BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT03349710
- Locations
- 🇺🇸
Cancer Treatment Centers of Phoneix, Goodyear, Arizona, United States
🇺🇸Pinnacle Research Group, Llc, Anniston, Alabama, United States
🇺🇸UCLA Health, Los Angeles, California, United States
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
- Conditions
- Malignancies Multiple
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 53
- Registration Number
- NCT03346837
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT03341390
- Locations
- 🇺🇸
PPD Austin Clinic, Austin, Texas, United States
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 292
- Registration Number
- NCT03338790
- Locations
- 🇺🇸
Local Institution - 0037, Miami, Florida, United States
🇺🇸Local Institution - 0009, Marietta, Georgia, United States
🇺🇸Local Institution - 0012, Detroit, Michigan, United States
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- Biological: CabiralizumabBiological: Nivolumab
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 205
- Registration Number
- NCT03336216
- Locations
- 🇺🇸
Local Institution - 0006, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 0007, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute., Boston, Massachusetts, United States
A Study of Experimental Medication BMS-986235 in Healthy Subjects
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 122
- Registration Number
- NCT03335553
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
🇺🇸Anaheim Clinical Trials, Anaheim, California, United States
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
- Conditions
- Advanced Cancer
- Interventions
- Biological: NivolumabBiological: IpilimumabBiological: RelatlimabBiological: CabiralizumabRadiation: Radiation Therapy
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT03335540
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Local Institution - 0001, Chicago, Illinois, United States
🇺🇸Local Institution - 0003, Pittsburgh, Pennsylvania, United States
The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: Non-interventional
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 265
- Registration Number
- NCT03331393
- Locations
- 🇺🇸
Local Institution, Richland, Washington, United States
🇺🇸Medication Management, LLC, Greensboro, North Carolina, United States
🇺🇸Local Institution - 0005, Gainesville, Georgia, United States
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
- Conditions
- MelanomaSkin Cancer
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT03329846
- Locations
- 🇺🇸
Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University Of Chicago, Chicago, Illinois, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
- Conditions
- Rheumatoid ArthritisPsoriasisAnkylosing SpondylitisInflammatory Bowel DiseasesNonalcoholic Steatohepatitis
- Interventions
- Other: Placebo
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 38
- Registration Number
- NCT03329885
- Locations
- 🇳🇱
Local Institution, Groningen, Netherlands